# AbbVie

> AbbVie discovers, develops, manufactures and sells prescription medicines and aesthetic products worldwide. Created through Abbott’s 2013 separation, it built a business beyond Humira through Skyrizi, Rinvoq, partnerships and acquisitions including Allergan. It reported $61.160 billion in 2025 net revenue.

- **Founded:** 2013
- **Headquarters:** North Chicago, United States
- **Founders:** Abbott Laboratories (Originating parent company; AbbVie became independent through a spin-off, not an individual-led startup)
- **Products:** Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib), Botox Therapeutic and Botox Cosmetic, Juvederm
- **Notable:** Established as an independent public company on January 1, 2013., Completed Allergan acquisition on May 8, 2020., Skyrizi and Rinvoq generated a calculated combined $25.866 billion in 2025 net revenues.

## Products & services

- **Humira (adalimumab)** — Anti-TNF biologic for several immune-mediated diseases; inherited at separation from Abbott.
- **Skyrizi (risankizumab)** — IL-23 inhibitor used in psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis under country-specific approvals; developed with Boehringer Ingelheim.
- **Rinvoq (upadacitinib)** — Oral JAK inhibitor for multiple inflammatory diseases; approved uses and safety restrictions vary by indication and country.
- **Botox Therapeutic and Botox Cosmetic** — Botulinum toxin products for approved medical and aesthetic uses; added through the Allergan acquisition. Date denotes acquisition, not original launch.
- **Juvederm** — Dermal fillers in the Allergan Aesthetics portfolio; date denotes acquisition.
- **Venclexta / Venclyxto (venetoclax)** — BCL-2 inhibitor for certain blood cancers, developed with Roche/Genentech.
- **Epkinly / Tepkinly (epcoritamab)** — Bispecific antibody for certain B-cell lymphomas, developed with Genmab.
- **Ubrelvy and Qulipta** — Migraine treatments for acute attacks and prevention, respectively; dates differ by product.
- **Vraylar (cariprazine)** — Psychiatric medicine developed with Gedeon Richter; acquired into AbbVie’s portfolio through Allergan.
- **myAbbVie Assist** — Eligibility-based U.S. medicine assistance for uninsured patients or people with limited coverage.

## Achievements

- Established as an independent public company on January 1, 2013.
- Completed Allergan acquisition on May 8, 2020.
- Skyrizi and Rinvoq generated a calculated combined $25.866 billion in 2025 net revenues.
- 2025 total net revenues exceeded the 2022 level despite the decline of Humira.
- FDA approved Rinvoq in 2023 as the first oral treatment for moderately to severely active Crohn’s disease in the specified eligible adult population.

## Latest updates

- **2026-10** — October 20: announced McLaren Racing partnership and Race to Innovate patient-advocacy campaign.
- **2026-07** — July 31: reported Q2 net revenues of $16.990 billion, up 10.2% on a reported basis.
- **2026-02** — February 4: reported 2025 full-year net revenues of $61.160 billion.
- **2025-09** — September 30: began construction on a $70 million Worcester biologics manufacturing and R&D expansion.

## Links

- Website: https://www.abbvie.com/
- LinkedIn: https://www.linkedin.com/company/abbvie
- Twitter/X: https://twitter.com/abbvie
- YouTube: https://www.youtube.com/user/AbbVie
- Instagram: https://www.instagram.com/abbvie/
- Facebook: https://www.facebook.com/AbbVieCareers

---

Profile page: https://yespress.io/abbvie
Published by YesPress — https://yespress.io
Last updated: 2026-10-22